Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pCAhCD40L (#RDB03915)

Expression vector of human CD40 ligand.

Clone info. Expression vector of human CD40 ligand driven by CA promoter.
Vector backbone pCAcc (Plasmid)
Selectable markers Amp^r
Gene/insert name Human CD40 ligand cDNA
Depositor|Developer Hamada, Hirofumi |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Additional terms and conditions:
Regarding resources containing CAG promoter: In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation for the CAG promoter (Niwa, H., Yamamura, K., Miyazaki, J., Gene 108 : 193-200, 1991) and an acknowledgment to Dr. Jun-ich Miyazaki of the Osaka University are requested.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 非営利機関の非営利学術研究へ提供する。利用者が本件リソースを利用した研究成果に基づき特許申請、商業活動等を行う場合は、利用者は事前に寄託者に連絡する。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。
MTAに書く付加的使用条件：
CAGプロモータを含むリソースについて: 利用者は、研究成果の公表にあたってCAGプロモータの文献 (Niwa, H., Yamamura, K., Miyazaki, J., Gene 108 : 193-200, 1991)を引用し、大阪大学 宮崎純一博士への謝辞の表明を必要とする。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB03915 pCAhCD40L DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pCAhCD40L was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB03915).

Reference section:

Tomihara, K., Kato, K., Masuta, Y., Nakamura, K., Tanaka, T., Hiratsuka, H., Hamada, H., Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int. J. Cancer 120 (7): 1491-1498 (2007). PMID 17205529. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB12774_A4Dip1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: pAxCA_F1
Sequence file: RDB12774_A4Dia.seq check
>03915_12774_A4Di_pAxCA_F1_E12_05_ABI08.ab1
    1 CGAACACCCC GGGTTGCTAC ATGTTCATGC CTTCTTCTTT TTCCTACAGC TCCTGGGCAA
   61 CGTGCTGGTT ATTGTGCTGT CTCATCATTT TGGCAAAGAA TTCAGCATGA TCGAAACATA
  121 CAACCAAACT TCTCCCCGAT CTGCGGCCAC TGGACTGCCC ATCAGCATGA AAATTTTTAT
  181 GTATTTACTT ACTGTTTTTC TTATCACCCA GATGATTGGG TCAGCACTTT TTGCTGTGTA
  241 TCTTCATAGA AGGTTGGACA AGATAGAAGA TGAAAGGAAT CTTCATGAAG ATTTTGTATT
  301 CATGAAAACG ATACAGAGAT GCAACACAGG AGAAAGATCC TTATCCTTAC TGAACTGTGA
  361 GGAGATTAAA AGCCAGTTTG AAGGCTTTGT GAAGGATATA ATGTTAAACA AAGAGGAGAC
  421 GAAGAAAGAA AACAGCTTTG AAATGCAAAA AGGTGATCAG AATCCTCAAA TTGCGGCACA
  481 TGTCATAAGT GAGGCCAGCA GTAAAACAAC ATCTGTGTTA CAGTGGGCTG AAAAAGGATA
  541 CTACACCATG AGCAACAACT TGGTAACCCT GGAAAATGGG AAACAGCTGA CCGTTAAAAG
  601 ACAAGGACTC TATTATATCT ATGCCCAAGT CACCTTCTGT TCCAATCGGG AAGCTTCGAG
  661 TCAAGCTCCA TTTATAGCCA GCCTCTGCCT AAAGTCCCCC GGTAGATTCG AGAGAATCTT
  721 ACTCAGAGCT GCAAATACCC ACAGTTCCGC CAAACCTTGC GGGCAACAAT CCATTCACTT
  781 GGGAGGAGTA TTTGAATTGC AACCAGGTGC TTCGGTGTTT GTCAATGTGA CTGATCCAAG
  841 CCAAGTGAGC CATGGCACTG GCTTCACGTC CTTTGGCTTA CTCAAACTCT GAGGATCTTT
  901 TTCCCTCTGC CAAAAATTAT GGGGGACATC ATGAAGCCCC TTTGAGCATC TGACTTTCTG
  961 GGCTATAAAG GAAATTTATT TTTCATTGCA TAGTGTGGTG GAGTTTTTTT TGTGTCTCTC
 1021 CACTTCGGAC GACATATGGA GGCCAATTCC ATTAACATCG GACTGAGAAT TGCTTAGGAG
1081 TTTGTGGCA
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Tomihara, K., Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int. J. Cancer 120 (7): 1491-1498 (2007). PMID 17205529. [link to RRC of NBRP]